Why OncoGenex (OXGI) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) -- OncoGenex  (OGXI) plummeted more than 55% to a one-year low of $4.16 on Monday after the pharmaceutical company announced along with Teva Pharmaceuticals  (TEVA) that their experimental prostate cancer treatment failed to show any statistically significant improvements when compared to standard chemotherapy in a late-stage trial.

The study contained 1,022 patients and tested the efficacy of the drug, custirsen, in conjunction with standard chemotherapy when compared to chemotherapy by itself. The drug did not show any improvements in the survival of patients with untreated metastatic castrate-resistant prostate cancer.

Custirsen is OncoGenex's lead drug candidate and is designed to decrease the production of the protein clusterin, which could be a major factor in cancer cell survival and resistance to treatments. The drug is also in development as a second-line treatment for mCRPC, and is also under evaluation for use in lung cancer.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

OGXI Chart

OGXI data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

8 Breakout Stocks Under $10 to Trade for Big Profits

4 Stocks Under $10 to Trade for Big Breakouts

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today